The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An update on the SUMMIT trial: bezuclastinib in non-advanced systemic mastocytosis
Lindsay Rein, MD, Duke University Medical Center, Durham, NC, discusses the ongoing Phase II SUMMIT trial (NCT05186753) evaluating bezuclastinib in non-advanced systemic mastocytosis. The first portion of the trial demonstrated that a daily 100mg oral dose is well-tolerated and reduces biomarkers of mast cell burden in most patients. Patients also reported an improvement in symptom severity and better overall well-being with this treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie Pharmaceuticals, Sobi, Incyte Corporation, Morphosys, Novartis, Sumitomo Dainippon Pharma Oncology; Institutional Principal Investigator: Incyte Corporation, Novartis, Sumitomo, PharmaEssentia, Geron, Protagonist, Karyopharm, Silence Therapeutics, Blueprints Medicine, Cogent, Merck.
